On November 1, 2023 Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, reported that data from the Phase 2 portion of its Phase 1-2 study of ST101 will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 15-19, 2023, in Vancouver, Canada (Press release, Sapience Therapeutics, NOV 1, 2023, View Source [SID1234636675]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details:
Title: "Neoadjuvant treatment with monotherapy ST101, C/EBPβ antagonist, triggers necrosis as a pathological response in newly diagnosed glioblastoma patients. Tissue-based analysis from a surgical window of opportunity clinical trial."
Poster Number: CTNI-44
Date and Time: Friday, November 17, 2023, 7:30 pm – 9:30 pm PT
Presenter: Fabio M. Iwamoto, Division of Neuro-Oncology, New York-Presbyterian/Columbia University Medical Center
More information can be found on the 2023 SNO website.
About ST101
ST101, a first-in-class antagonist of C/EBPβ, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors (NCT04478279). In the ongoing Phase 2 dose expansion part of the study, ST101 has demonstrated clinical proof-of-concept in recurrent GBM (rGBM) with a mRANO-confirmed partial response and long-lasting stable disease in several additional patients. In the ongoing neo-adjuvant GBM sub-study, ST101 is being evaluated as a monotherapy in rGBM and in combination with radiation and temozolomide in newly diagnosed GBM (ndGBM).
ST101 has been granted Fast Track designation for rGBM from the U.S. FDA and orphan designations for glioma from the U.S. FDA and the European Commission.